LONDON/ZURICH (Reuters) – Johnson & Johnson boosted its research efforts into battling Alzheimer’s on Monday, striking a deal potentially worth more than $500 million to develop anti-tau vaccines with Swiss biotech firm AC Immune.
Tau is a protein known for forming twisted fibers inside brain cells and is linked to cell death. It is one of two abnormal proteins tied to the memory-robbing disease. The other is beta amyloid.
Good news – British #Ebola patient Pauline Cafferkey improving https://t.co/a2S9mTAVHK
LONDON (Reuters) – Shire Plc has agreed to buy NPS Pharmaceuticals Inc for $5.2 billion in its biggest acquisition yet, as the Dublin-based drugmaker strengthens its position in the lucrative field of medicines for rare diseases.
The takeover continues the breakneck pace of deal-making seen in 2014 in the pharmaceuticals sector, where companies are jockeying for promising assets as a wave of new drugs emerges from research laboratories.
LONDON (Reuters) – An experimental cannabis drug failed to alleviate pain in cancer patients as hoped in a clinical study, sending shares in its British maker GW Pharmaceuticals as much as 21 percent lower on Thursday.
GW, which is developing the drug Sativex for pain in collaboration with Japan’s Otsuka, said the first of three late-stage trials found no statistically significant difference between subjects using its product and those given a placebo.